160801-26-3

Usage

Uses

Used in Nutritional Supplements:
Docosahexaenoic Acid N-Succinimide is used as a nutritional supplement to support the health of the brain and retina, given its role as a major structural component in their excitable membranes. It is particularly beneficial for individuals seeking to enhance cognitive function and maintain optimal eye health.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, Docosahexaenoic Acid N-Succinimide may be used as an active ingredient or additive in the development of medications targeting brain and eye health. Its presence in the excitable membranes of these organs makes it a promising candidate for therapeutic applications.
Used in Nutraceutical Applications:
Docosahexaenoic Acid N-Succinimide is also utilized in the nutraceutical industry, where it is incorporated into products designed to promote overall health and well-being. Its role in supporting brain and eye health makes it a valuable addition to nutraceutical products aimed at enhancing cognitive function and vision.
Used in Research and Development:
In the field of research and development, Docosahexaenoic Acid N-Succinimide is employed as a key compound in the study of brain and eye health, as well as in the development of new pharmaceutical and nutraceutical products. Its unique properties and functions make it an essential tool for scientists and researchers working in these areas.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 6217-54-5 docosahexaenoic acid 

Downstream Products

• 129024-87-9 (4Z,7Z,10Z,13Z,16Z,19Z)-N-(3,4-dihydroxyphenethyl)docosa-4,7,10,13,16,19-hexaenamide 

Relevant academic research and scientific papers

Unsaturated acyl chains dramatically enhanced cellular uptake by direct translocation of a minimalist oligo-arginine lipopeptide

The recurring issue with cell penetrating peptides is how to increase direct translocation vs. endocytosis, to avoid premature degradation. Acylation by a cis unsaturated chain (C22:6) of a short cationic peptide provides a new rational design to favour diffuse cytosolic and dense Golgi localisations.

Dextran-docosahexaenoic acid coupled polymer, and synthesis method and application thereof

The invention provides a dextran-docosahexaenoic acid coupled polymer, and a synthesis method and application thereof, and belongs to the technical field of biological medicines. The structural formula of the dextran-docosahexaenoic acid (DHA) coupled polymer is shown in the specification, water solubility of DHA can be improved, and the problem of difficult administration caused by poor water solubility of DHA is solved. Meanwhile, serving as an amphiphilic drug carrier tool, the dextran-docosahexaenoic acid coupled polymer can be further coupled with other drugs, so that the characteristicsof the original drugs are changed. The anti-tumor effect of drugs can be enhanced due to release of DHA in vivo when the anti-tumor chemotherapy drugs are entrapped. Meanwhile, the synthesis method issimple, convenient and feasible and is high in operability, so that the synthesis method has a good practical application value.

STRUCTURED MOLECULAR VECTORS FOR ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF

The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and/or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and/or in traumatic brain injuries and/or in a neuroinflammatory disease, and/or in a neurodegenerative disease.

DHA (docosahexaenoic acid)-MMC (mitomycin C) derivative and preparation method and application thereof

The invention discloses a DHA (docosahexaenoic acid)-MMC (mitomycin C) derivative. A structure formula thereof is shown in the description. The invention also discloses application of the derivative in preparing medicines for resisting pterygium, and a preparation method of the derivative. The preparation method specifically comprises the following steps of mixing DHA-NHS and a buffer solution, stirring, adding MMC, concentrating to the dry state, and separating the remained matter by silica gel column chromatography. The preparation method has the advantages that the MMC and the DHA are prepared into the larger-molecule derivative, namely the DHA-MMC, by a chemical synthesizing method, so that the molecular weight of the medicine is increased from 334 (use of single MMC) to 649, the absorbing in eyes via cornea is difficult, and the side effect in eyes is reduced; after accumulating to the conjunctiva and pterygium tissues, the derivative is gradually hydrolyzed to release the MMC to take effect; by utilizing the tumor inhibiting property and targeting property of the DHA, the selectivity and inhibiting property of the pterygium tissue of the DHA-MMC are enhanced.

Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein

The inventors disclose here a novel, facile approach to the synthesis of acetonide-protected catechol-containing compounds having at least one amine group. In specific embodiments, the invention provides novel methods of synthesizing 3,4-dihydroxyphenylalanine (H-DOPA(acetonide)-OH (6)), Fmoc-protected H-DOPA(acetonide)-OH (Fmoc-DOPA(acetonide)-OH (7)), Fmoc-protected dopamine (Fmoc-dopamine(acetonide) (10)), TFA-protected dopamine (TFA-dopamine(acetonide) (13)) and acetonide-protected 4-(2-aminoethyl)benzene-1,2-diol (acetonide-protected dopamine (14)).

Acetonide protection of dopamine for the synthesis of highly pure N-docosahexaenoyldopamine

Direct acetonide protection of the catechol of dopamine has proven to be problematic due to the formation of Pictet-Spengler isoquinolines. Here we report an efficient method for acetonide protection of dopamine, allowing the preparation of a dopamine prodrug without complications from the Pictet-Spengler reaction. Acetonide-protected dopamine was first synthesized by pre-protecting the amino group with phthaloyl followed by refluxing with 2,2-dimethoxypropane in the presence of TsOH. Further work demonstrated that Fmoc and trifluoroacetyl were also suitable N-protective groups, while Boc-protected dopamine gave an isoquinoline product. Acetonide-protected dopamine was coupled to DHA (all cis-4,7,10,13,16,19-docosahexaenoic acid) to produce the N-DHA-dopamine prodrug with high purity.